Dont have an account?Sign up here
3 May 2012
New research raises the possibility of identifying which specific breast cancer patients could benefit from a promising new drug.
Everolimus has been shown in a large clinical trial to benefit older women with the most common type of advanced breast cancer. It could delay the progression of the disease for four months more than the current treatments.
The research presented at the Impakt Breast Cancer Conference in Brussels, Belgium, raises the possibility of a test to identify which patients within this group could most benefit from the drug.
Everolimus is currently at the beginning of the appraisal process carried out by NICE (the National Institute for Health and Clinical Excellence). Following this process, it may be then made available for use on the NHS for breast cancer patients.
Dr Caitlin Palframan, Policy Manager at Breakthrough Breast Cancer, says: “This is a very promising drug for breast cancer patients and this research identifies a specific group who may respond better to this treatment. While this research is at an early stage, it could be crucial in making sure the patients who receive this drug are those most likely to benefit.
“Everolimus is currently being considered for use on the NHS for breast cancer patients following very encouraging clinical trial results.”